Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Active Primary Sjogren's Syndrome
NCT05016297Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2022
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in Sjogren's syndrome, sponsored by Peking Union Medical College Hospital. Started Jul 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT05016297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05016297.